Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers

HIV Clinical Trials

Volumn 10, Issue 1, 2009, Pages 25-32

  Butt, Adeel ^a,b,f   Khan, Uzma ^c   Shaikh, Obaid ^a   McMahon, Deborah ^a   Dorey Stein, Zachariah ^d   Tsevat, Joel ^e   Lo Re III, Vincent ^d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Center for Health Equity Research and Promotion   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Coinfection; Comorbidities; Contraindications; HCV; HIV; Treatment eligibility

Indexed keywords

ADULT; ALCOHOL ABUSE; ARTICLE; DEPRESSION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PRIORITY JOURNAL; STRUCTURED INTERVIEW; TERTIARY HEALTH CARE; TREATMENT PLANNING; UNIVERSITY HOSPITAL;

EID: 64949160391     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1001-25     Document Type: Article

References (30)

1. Zeuzem S, Feinman SV, Rasenack J, Heathcote J, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
4. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
5. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med. 2004;351:438-450.
6. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005;12:81-85.
7. Butt AA, Justice AC, Skanderson M, Rigsby M, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-389.
8. Butt AA, Justice AC, Skanderson M, Good CB, Kwoh CK. Rates and predictors of HCV treatment in HCV-HIV coinfected persons. Aliment Pharmacol Ther. 2006;24: 585-591.
9. Fultz SL, Justice AC, Butt AA, Rabeneck L, Rodriguez-Barradas MC, Weissman S. Testing, referral, and treatment patterns for hepatitis C coinfection in a cohort of veterans with HIV infection. Clin Infect Dis. 2003;36:1039-1046.
10. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93:141-147.
11. Cacoub P, Halfon P, Rosenthal E, Pialoux G, Benhamou Y, Perronne C, Pol S. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": Modifications in two large surveys between 2004 and 2006. J Hepatol. 2008;48:35-42.
12. Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodefi ciency virus coinfection: From large trials to real life. J Viral Hepat. 2006;13:678-682.
13. Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS. 2005;19(Suppl 3):S208-214.
14. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20:754-758.
15. Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu KQ, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772-1779.
16. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004;39: 999-1007.
17. Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program office. Am J Gastroenterol. 2006;101: 2360-2378.
18. Management of Hepatitis C: 2002. National Institutes of Health Consensus Conference Statement. 2002;19:1-46. Available at: http://consensus. nih.gov/2002/2002Hepatitis C2002116html.htm
19. APASL Hepatitis C Working Party. Asian Pacifi c Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615-633.
20. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kwoh CK. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat. 2007;14:890-896.
21. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908-914.
22. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS. 2005;19(Suppl 3):S99-S105.
23. Justice AC, McGinnis KA, Atkinson JH, Heaton RK, Young C, Sadek J, et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004;18(Suppl 1):S49-59.
24. Sherman KE, Zhou Y, Daria D, Fichtenbaum CJ, Butt AA, Andersen J, et al. High frequency of anemia in HCV-HIV coinfected persons receiving weight based ribavirin and zidovudine. Presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-15, 2005; San Francisco, CA.
25. Butt AA, Herrine S. Hepatitis C. In: Yu VL, Weber R, Raoult D, eds. Antimicrobial Therapy and Vaccines. 2nd ed. New York: Apple Tree Productions; 2002.
26. Butt AA, Singh N. Hepatitis C. Prevention, therapy and role of transplantation. In: Wenzel R, ed. Prevention and Control of Nosocomial Infections. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2003.
27. Heathcote J. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis. 2000;20:185-199.
28. Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report. Gut. 2000;47:694-697.
29. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40:993-999.
30. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.